We are live on ! Find out more
RNTX icon

Rein Therapeutics

40 hedge funds and large institutions have $9.8M invested in Rein Therapeutics in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,339% more capital inflows, than outflows

Capital inflows: $2.43M | Capital outflows: $99.5K

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

11% more funds holding

Funds holding: 36 → 40 (+4)

6.38% more ownership

Funds ownership: 30.05% → 36.43% (+6.4%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

13% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 8

Holders
40
Holders Change
+4
Holders Change %
+11.11%
% of All Funds
0.52%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
6
Increased
7
Reduced
8
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

RNTX Hedge Fund Activity: Q3 2025 in Review

40 of the 7,665 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q3 2025, worth a combined $9.8M — up 2.3% from $9.5M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new RNTX positions and 2 closed out — a net gain of 4 holders — while 7 added to existing stakes and 8 trimmed.

The largest buyer was Voss Capital, adding an estimated $1.57M. The largest seller was Sigma Planning, cutting an estimated $29.1K.

  • 40 institutional investors held Rein Therapeutics (RNTX) as of Q3 2025, up from 36 in Q2 2025.
  • Funds reported $9.8M of Rein Therapeutics stock for Q3 2025, up 2.3% quarter-over-quarter.
  • 6 funds opened new Rein Therapeutics positions in Q3 2025 and 2 closed out, a net change of +4 holders.
  • The largest Rein Therapeutics buyer in Q3 2025 was Voss Capital, an estimated $1.57M added.
  • The largest Rein Therapeutics seller in Q3 2025 was Sigma Planning, an estimated $29.1K sold.

Based on aggregated 13F filings for Q3 2025.